Survival Outcomes
The five-year OS throughout the time-period of 1997-2013 was 63% (95% CI: 53 – 74%) while EFS at five years was observed to be 59% (95% CI: 49 – 71%) (Figure 2A ). The 5-year OS and EFS estimates for those diagnosed post-2008 were observed to be 47% (95% CI: 33 – 68%) and 42% (28 – 62%), and the 5-year OS and EFS for those diagnosed pre-2008 were 74% (95% CI: 62 – 88%) and 72% (95% CI: 60 – 86%), respectively (Figure 2B ). Five-year EFS rates by histology were: desmoplastic/nodular 66% (95% CI: 43-100%), anaplastic 20% (95% CI: 6-69%), classic 55% (95% CI: 36-84%), or other/undefined 69% (95% CI: 56-84%) (Figure 2C ). Five-year OS rates by histology were: desmoplastic/nodular 74% (95% CI: 52 – 100%), anaplastic 30% (95% CI: 12 – 77%), classic 54% (95% CI: 34 – 83%), or other/undefined histology 71% (95% CI: 58 – 86%) . M-stage information was only available for those diagnosed post-2008; in this subgroup, the 5-year EFS for those with no metastases at diagnosis (M0) was 54% (95% CI: 36 – 81%) and for those with observed metastases (M1+) was 13% (95% CI: 2 – 78%) (Figure 2D). Lastly, the five-year OS rate for residual tumors less than 1.5cm2 was 50% (95% CI: 32 – 79%) and 44% (95% CI: 26 – 77%) for residual tumors greater than 1.5cm2.